Shire in the hunt for promising new stem cell tech

The UK's Shire has been making a series of small-$3 million to $5 million-investments in stem cell developers as the CEO continues to hunt for viable new business opportunities. "The science is there," said Angus Russell, "the challenge is finding something you can turn into a business." Russell makes clear that he's taking a distinctly unsentimental approach to stem cell research, noting that he only wants to acquire technology that insurers will be willing to pay for. Report

Suggested Articles

Quench Bio is going after a family of proteins involved in inflammatory cell death to treat inflammatory diseases in a more holistic way.

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.